These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 27263443)

  • 1. Xanthomata striata palmaris regression with fenofibrate in type III dyslipoproteinemia: A clinical report.
    Sampietro T; Sbrana F; Bigazzi F; Dal Pino B; Luciani R; Pianelli M; Marconcini C; Pisciotta L
    Nutr Metab Cardiovasc Dis; 2016 Sep; 26(9):848-50. PubMed ID: 27263443
    [No Abstract]   [Full Text] [Related]  

  • 2. [Part III. Clinical control of fenofibrate therapy].
    Clin Investig Arterioscler; 2016 Jul; 28 Suppl 3():20-5. PubMed ID: 27473467
    [No Abstract]   [Full Text] [Related]  

  • 3. Fenofibrate profiled as the fibrate with additional new data, supporting its use with statins in the European Medicines Agency recommendations.
    Cardiovasc J Afr; 2011; 22(1):55. PubMed ID: 21298212
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination lipid therapy in type 2 diabetes.
    Sacks FM; Carey VJ; Fruchart JC
    N Engl J Med; 2010 Aug; 363(7):692-4; author reply 694-5. PubMed ID: 20842772
    [No Abstract]   [Full Text] [Related]  

  • 5. Fenofibrate and Dyslipidemia: Still a Place in Therapy?
    Tarantino N; Santoro F; Correale M; De Gennaro L; Romano S; Di Biase M; Brunetti ND
    Drugs; 2018 Sep; 78(13):1289-1296. PubMed ID: 30159817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenofibrate lowers lipid parameters in obese dogs.
    Serisier S; Briand F; Ouguerram K; Siliart B; Magot T; Nguyen P
    J Nutr; 2006 Jul; 136(7 Suppl):2037S-2040S. PubMed ID: 16772490
    [No Abstract]   [Full Text] [Related]  

  • 7. Fenofibrate in the treatment of dyslipidemia associated with HIV infection.
    Samineni D; Fichtenbaum CJ
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):995-1004. PubMed ID: 20604734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Field, a randomized clinical trial of cardiovascular prevention with fenofibrate in type 2 diabetes].
    Radermecker RP; Scheen AJ
    Rev Med Liege; 2005 Dec; 60(12):957-61. PubMed ID: 16457397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes: Should we use fibrates in patients with diabetes and mild CKD?
    Lewis D; Wanner C
    Nat Rev Nephrol; 2012 Feb; 8(4):201-2. PubMed ID: 22349490
    [No Abstract]   [Full Text] [Related]  

  • 10. Diabetic retinopathy: treatment and prevention.
    Dodson PM
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S9-S11. PubMed ID: 17935059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleiotropic actions of fenofibrate on the heart.
    Balakumar P; Rohilla A; Mahadevan N
    Pharmacol Res; 2011 Jan; 63(1):8-12. PubMed ID: 21093591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More clinical lessons from the FIELD study.
    Fazio S
    Cardiovasc Drugs Ther; 2009 Jun; 23(3):235-41. PubMed ID: 19160032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment.
    Chan DC; Wong AT; Yamashita S; Watts GF
    Atherosclerosis; 2012 Apr; 221(2):484-9. PubMed ID: 22341868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].
    Im M; Kim M; Lee JK; Chang YH; Lee DY; Hong SI; Lee YY; Hong YJ
    Korean J Lab Med; 2010 Feb; 30(1):17-9. PubMed ID: 20197717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinopathy progression in type 2 diabetes.
    Baum SJ
    N Engl J Med; 2010 Nov; 363(22):2172; author reply 2173-4. PubMed ID: 21105808
    [No Abstract]   [Full Text] [Related]  

  • 16. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
    Pérez A
    Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
    [No Abstract]   [Full Text] [Related]  

  • 17. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
    Keating GM; Croom KF
    Drugs; 2007; 67(1):121-53. PubMed ID: 17209672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [What is the contribution of the review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidemia? Report on consensus of experts in the importance of the combined therapy by fenofibrate with statin].
    Rosolová H
    Vnitr Lek; 2015 Nov; 61(11):971-5. PubMed ID: 26652786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy.
    Harmer JA; Keech AC; Veillard AS; Skilton MR; Marwick TH; Watts GF; Meredith IT; Celermajer DS;
    Atherosclerosis; 2015 Sep; 242(1):295-302. PubMed ID: 26233916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
    Masana L; Cabré A; Heras M; Amigó N; Correig X; Martínez-Hervás S; Real JT; Ascaso JF; Quesada H; Julve J; Palomer X; Vázquez-Carrera M; Girona J; Plana N; Blanco-Vaca F
    Atherosclerosis; 2015 Feb; 238(2):213-9. PubMed ID: 25528430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.